Company intelligence / Profile preview

Prime Medicine, Inc.

Cambridge, Massachusetts, United Statesprimemedicine.com ↗

Ownership: Public · PRME
Development stage: Phase 1

Overview

Prime Medicine is advancing multiple programs in pre-clinical stages, with a focus on hematology, immunology & oncology, liver, and lung diseases. The company recently unveiled a program for Alpha-1 Antitrypsin Deficiency (AATD) in March 2025.

Therapeutic areas: ImmunologyRare DiseasesPulmonology
Modalities: Gene editingPrime Editing
Industry: Biotech

Drug pipeline

6 assets

PM359

5 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb (September 2024, for ex vivo T-cell Prime Editor products)Cystic Fibrosis Foundation (January 2024, up to $15 million to support development of Prime Editors for Cystic Fibrosis)

Financials

Market cap: $605.1M
Total revenue: $1.2M
Enterprise value: $622.5M

Beyond the preview

Go deeper on Prime Medicine, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prime Medicine, Inc..

Explore the full profile